Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZoetisXSWX:ZTS +0.67%56 Shiller PE Ratio is 16.19 as of Sep. 01, 2026, which is 71% below its 10-year median of 56.42. GuruFocus rates XSWX:ZTS with a GF Score™ of 56/100 and a GF Value™ of CHF147.86 (Significantly Undervalued). Among 526 Drug Manufacturers companies, Zoetis ranks better than 69.77% on this metric.
As of today (2026-09-01), Zoetis's current share price is CHF61.67. Zoetis's E10 for the quarter that ended in Jun. 2026 was CHF3.81. Zoetis's Shiller PE Ratio for today is 16.19.
The historical rank and industry rank for Zoetis's Shiller PE Ratio or its related term are showing as below:
XSWX:ZTS'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.53 Med: 56.42 Max: 110.74
Current: 16.52
During the past years, Zoetis's highest Shiller PE Ratio was 110.74. The lowest was 15.53. And the median was 56.42.
XSWX:ZTS's Shiller PE Ratio is ranked better than 69.77% of 526
companies
in the Drug Manufacturers industry
Industry Median: 25.59
vs XSWX:ZTS: 16.52
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Zoetis's adjusted earnings per share data for the three months ended in Jun. 2026 was CHF1.319. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is CHF3.81 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Zoetis Shiller PE Ratio Related Terms
Zoetis Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Zoetis's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ZTS vs UTHR, VTRS, NBIX: Shiller PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zoetis's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Zoetis's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Zoetis's Shiller PE Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis's E10 for the quarter that ended in Jun. 2026 is calculated as:
For example, Zoetis's adjusted earnings per share data for the three months ended in Jun. 2026 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Zoetis (XSWX:ZTS) has a Shiller PE Ratio of 16.19 as of Sep. 01, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Zoetis and its competitors. This is 71% below median its historical median of 56.42. Over the past decade, Zoetis' Shiller PE Ratio has ranged from 15.53 to 110.74. According to the industry distribution chart, Zoetis ranks #159 out of 526 companies in the Drug Manufacturers industry, placing it in the top 30.2%.
Is Zoetis' Shiller PE Ratio too high?
Zoetis' current Shiller PE Ratio of 16.19 is 71% below median its 10-year median of 56.42. Over the past 10 years, this metric has ranged from a low of 15.53 to a high of 110.74. The Drug Manufacturers industry median Shiller PE Ratio is 25.59. Zoetis' value of 16.19 is 36.7% below this industry median. Based on the distribution chart, Zoetis ranks #159 out of 526 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zoetis has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' Shiller PE Ratio compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #159 out of 526 companies for Shiller PE Ratio. This puts Zoetis in the upper half of its industry. The industry median Shiller PE Ratio is 25.59. Zoetis' value of 16.19 is 36.7% below this benchmark. Historically, Zoetis' own Shiller PE Ratio has ranged from 15.53 to 110.74 over the past decade. While the company's 10-year median is 56.42 vs. the industry median of 25.59, Zoetis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 25.59, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zoetis's current Shiller PE Ratio of 16.19 is 36.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Zoetis and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 25.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zoetis's current Shiller PE Ratio is 16.19, which is 71% below median its own 10-year median of 56.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (XSWX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF147.86, compared to a current price of CHF61.67 — trading 58.3% below its estimated fair value. The current Shiller PE Ratio is 16.19, which is 71% below median its 10-year median of 56.42 and 36.7% below the Drug Manufacturers industry median of 25.59. Zoetis' overall GF Score™ is 56/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Zoetis (XSWX:ZTS), the current Shiller PE Ratio is 16.19 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zoetis (XSWX:ZTS) Overvalued in 2026?
Based on GuruFocus' analysis, Zoetis stock appears to be undervalued.
The current stock price of CHF61.67 is trading 58.3% below its estimated GF Value™ of CHF147.86.
GuruFocus considers Zoetis to be Significantly Undervalued.
Key valuation signals for XSWX:ZTS:
Shiller PE Ratio: 16.19 (71% below median its 10-year median of 56.42)
GF Value™: CHF147.86 vs. price of CHF61.67 (58.3% below fair value)
Industry Position: 36.7% below the Drug Manufacturers median (#159 of 526)
No single metric tells the full story. See the XSWX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
56GF Score
Get the complete analysis for XSWX:ZTS
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZTS has been successfully added to your 
